UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 493

Sortiert nach

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Breast cancer research and treatment, 2018-06, Vol.169 (3), p.397-406

2018

Volltextzugriff (PDF)

Albumin-bound paclitaxel: a next-generation taxane

Expert opinion on pharmacotherapy, 2006-06, Vol.7 (8), p.1041-1053

Gradishar, William J

2006

Volltextzugriff (PDF)

Optimizing Breast Cancer Management

1st ed. 2018., 2018

Volltextzugriff (PDF)

Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?

The oncologist (Dayton, Ohio), 2018-10, Vol.23 (10), p.1153-1161

2018

Volltextzugriff (PDF)

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7794-7803

2005

Volltextzugriff (PDF)

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Cancer treatment reviews, 2017-02, Vol.53, p.111-119

2017

Volltextzugriff (PDF)

HER2 Therapy — An Abundance of Riches

The New England journal of medicine, 2012-01, Vol.366 (2), p.176-178

Gradishar, William J

2012

Volltextzugriff (PDF)

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Clinical cancer research, 2018-02, Vol.24 (3), p.560-568

2018

Volltextzugriff (PDF)

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

Immune Checkpoint Blockade for Breast Cancer

Cancer treatment and research, 2018, Vol.173, p.155-165

2018

Volltextzugriff (PDF)

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Breast cancer research and treatment, 2018-09, Vol.171 (2), p.371-381

2018

Volltextzugriff (PDF)

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Journal of clinical oncology, 2021-01, Vol.39 (1), p.79-89

2021

Volltextzugriff (PDF)

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3611-3619

2009

Volltextzugriff (PDF)

Long-term outcomes in cancer patients who did or did not pursue fertility preservation

Fertility and sterility, 2018-02, Vol.109 (2), p.349-355

2018

Volltextzugriff (PDF)

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.137-137, Article 137

2019

Volltextzugriff (PDF)

Satisfaction With Work-Life Balance and the Career and Retirement Plans of US Oncologists

Journal of clinical oncology, 2014-04, Vol.32 (11), p.1127-1135

2014

Volltextzugriff (PDF)

Role of Fcγ receptors in HER2-targeted breast cancer therapy

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e003171

2022

Volltextzugriff (PDF)

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE

Journal of clinical oncology, 2018-03, Vol.36 (8), p.741-748

2018

Volltextzugriff (PDF)

Leveraging Molecular Information for Optimal Treatment Recommendations

NEJM evidence, 2024-05, Vol.3 (5), p.EVIDe2400081

2024

Volltextzugriff (PDF)

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Molecular cancer therapeutics, 2017-07, Vol.16 (7), p.1412-1420

2017

Volltextzugriff (PDF)

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor‐Positive Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2017-05, Vol.22 (5), p.507-517

2017

Volltextzugriff (PDF)

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

Journal of clinical oncology, 2009-01, Vol.27 (1), p.127-145

2009

Volltextzugriff (PDF)

New Approaches to Endocrine Therapy for Breast Cancer

Journal of the National Comprehensive Cancer Network, 2017-05, Vol.15 (5S), p.679

Gradishar, William J

2017

Volltextzugriff (PDF)

1 – 25 von 493

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(473)
Mit Volltextzugriff
(413)

Publikationsform

Sprache

Englisch
(493)
Japanisch
(29)
Russisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(257)
Female
(231)
Science & Technology
(222)
Life Sciences & Biomedicine
(219)
Oncology
(185)
Breast Neoplasms - Drug Therapy
(133)
Breast Cancer
(124)
Breast Neoplasms - Pathology
(91)
Middle Aged
(75)
Adult
(66)
Aged
(59)
Chemotherapy
(51)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(50)
Breast Neoplasms - Therapy
(50)
Biological And Medical Sciences
(46)
Medical Sciences
(46)
Neoplasm Staging
(41)
Chemotherapy, Adjuvant
(40)
Tumors
(40)
Treatment Outcome
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Albumin-bound paclitaxel: a next-generation taxane

Optimizing Breast Cancer Management

Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

HER2 Therapy — An Abundance of Riches

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Immune Checkpoint Blockade for Breast Cancer

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

Long-term outcomes in cancer patients who did or did not pursue fertility preservation

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Satisfaction With Work-Life Balance and the Career and Retirement Plans of US Oncologists

Role of Fcγ receptors in HER2-targeted breast cancer therapy

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE

Leveraging Molecular Information for Optimal Treatment Recommendations

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor‐Positive Metastatic Breast Cancer

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

New Approaches to Endocrine Therapy for Breast Cancer

Suchergebnisse filtern